Goldman Sachs Initiates Coverage of DexCom (WBAG:DXCM) with Buy Recommendation

Goldman Sachs initiated coverage of DexCom (WBAG:DXCM) with a Buy recommendation on May 30, 2025, while the average one-year price target suggests a 32.99% upside to € 100,91/share based on analyst forecasts. Despite a projected 26.11% increase in annual revenue to 5,231MM, the number of institutions holding DexCom decreased by 3.76% in the last quarter, though total shares owned by institutions increased slightly by 1.01%.

Analysis

Goldman Sachs initiated coverage on DexCom (DXCM) with a "Buy" recommendation on May 30, 2025, citing an average one-year price target of €100.91 as of December 20, 2023, which suggests a notable 32.99% upside from its latest closing price of €75.88 per share. This outlook is supported by DexCom's projected annual revenue of 5,231MM, representing a 26.11% increase, and a projected non-GAAP EPS of 2.20. Institutional sentiment, however, presents a more nuanced picture: while total shares owned by institutions increased marginally by 1.01% to 436,857K shares and the average portfolio weight in DXCM edged up by 1.38%, the number of institutions reporting positions decreased by 3.76% (71 owners) in the last quarter. Analysis of major shareholders reveals divergent shareholding changes but a consistent trend in portfolio allocation adjustments. Baillie Gifford reduced its share count by 3.05% and its portfolio allocation to DXCM by 63.38%. Capital Research Global Investors decreased holdings by 19.40% and allocation by 22.22%. Conversely, Jennison Associates increased its share count by a significant 27.36%. Vanguard's VTSMX and VFINX index funds also reported modest increases in shares held (0.81% and 2.62% respectively). Despite these varied changes in absolute share counts, all these named major shareholders, including Jennison Associates and the Vanguard funds, decreased their relative portfolio allocation to DXCM over the last quarter, indicating a broader strategic re-weighting or risk management across these institutions.

Key Decisions for Investors

• Investors should consider the positive catalyst of Goldman Sachs' 'Buy' initiation and the significant 32.99% price target upside, which are underpinned by strong projected revenue and EPS growth for DexCom.
• Carefully evaluate the mixed institutional signals, particularly the decline in the number of fund owners and the consistent reduction in portfolio allocation to DXCM by several major shareholders, even those increasing absolute share counts, as this may indicate strategic de-risking or profit-taking.
• Monitor the divergent activities of large shareholders, such as the substantial share reduction by Capital Research versus the significant increase by Jennison Associates, to gauge differing institutional convictions regarding DexCom's valuation and prospects.